Agilent has just introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next-generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.
The new assay, developed with Dr. Rene Bernards of the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, targets genes for greater than 500 known kinases plus a number of cancer genes and untranslated regions.
“Being able to target approximately 500 kinase genes simultaneously provides us with a significant advantage to link kinase mutations with disease states with the potential to individualize therapy for each cancer patient,” said Dr. Bernards. “Using the knowledge gained from our SureSelect studies, we could better stratify patient populations for specific targeted therapies. With the human kinome kit we focus our research specifically on kinases, as mutations in these genes are frequently strong biomarkers of response to targeted cancer therapies. By focusing on a limited set of genes, we can maximize our sequencing depth and reduce overall sequencing expense.”
“Agilent’s collaboration with Dr. Bernards has resulted in the development of a human kinome kit that enriches for the most comprehensive set of kinase and kinase-related genes,” said Emily LeProust, Ph.D, Agilent director, Applications and Chemistry R&D – Genomics. “The kit will enable scientists to efficiently map mutations across the genome, accelerate biomarker discovery and allow for better stratification of patient populations.”